Collaboration provides opportunity to expand on Alexion’s two decades of complement leadership Complement Pharma to receive up to a total of € 14 million in milestone-dependent payments through Phase ...
- Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to three additional targets, in the complement pathway - - Zealand Pharma to receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results